205 related articles for article (PubMed ID: 29684967)
41. Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
Park SH; Ye BD; Yang SK
Gut Liver; 2022 Jan; 16(1):138-140. PubMed ID: 34373365
[No Abstract] [Full Text] [Related]
42. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
Kucharzik T; Koletzko S; Kannengiesser K; Dignass A
Dtsch Arztebl Int; 2020 Aug; 117(33-34):564-574. PubMed ID: 33148393
[TBL] [Abstract][Full Text] [Related]
43. Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report.
Shimodaira Y; Takahashi S; Iijima K
BMC Gastroenterol; 2021 May; 21(1):207. PubMed ID: 33964871
[TBL] [Abstract][Full Text] [Related]
44. Characteristic Changes of Ulcerative Colitis-Associated Neoplasm Patients in the Era of Biologics: a 20-Year Single Institution Experience of Surgical Cases.
Kato H; Seishima R; Matsui S; Shigeta K; Okabayashi K; Kitagawa Y
J Gastrointest Surg; 2023 Dec; 27(12):3076-3079. PubMed ID: 37940805
[No Abstract] [Full Text] [Related]
45. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis.
Abraham B; Glassner K
Curr Opin Gastroenterol; 2021 Jul; 37(4):344-350. PubMed ID: 33731642
[TBL] [Abstract][Full Text] [Related]
46. Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists.
White S; Morrow R; Pan I; de Zoeten EF
J Pediatr Gastroenterol Nutr; 2023 Jun; 76(6):701-703. PubMed ID: 36867849
[No Abstract] [Full Text] [Related]
47. Pathological mechanism and targeted drugs of ulcerative colitis: A review.
Guo M; Wang X
Medicine (Baltimore); 2023 Sep; 102(37):e35020. PubMed ID: 37713856
[TBL] [Abstract][Full Text] [Related]
48. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis.
Na SY; Choi CH; Song EM; Bang KB; Park SH; Kim ES; Park JJ; Keum B; Lee CK; Lee BI; Ryoo SB; Koh SJ; Choi M; Kim JS;
Intest Res; 2023 Jan; 21(1):61-87. PubMed ID: 35645321
[TBL] [Abstract][Full Text] [Related]
49. Second Korean guidelines for the management of ulcerative colitis.
Choi CH; Moon W; Kim YS; Kim ES; Lee BI; Jung Y; Yoon YS; Lee H; Park DI; Han DS;
Intest Res; 2017 Jan; 15(1):7-37. PubMed ID: 28239313
[TBL] [Abstract][Full Text] [Related]
50. Sustained effect of leukocytapheresis/granulocytapheresis versus anti-human TNF-α monoclonal antibody on ulcerative colitis: A 2-year retrospective study.
Sakai M; Hayashi K; Ito T; Otani H; Mori Y; Ito S; Endo K; Matsuda H; Yoshino K; Kitamura K; Kubota E; Motomura Y; Suzuki Y; Fujitani S; Suzuki T
Medicine (Baltimore); 2023 Apr; 102(16):e33368. PubMed ID: 37083800
[TBL] [Abstract][Full Text] [Related]
51. Biologics Targeting in the Treatment of Inflammatory Bowel Disease: A Conundrum.
Rehman M; Cancarevic I; Iskander B; Lalani S; Malik BH
Cureus; 2020 Sep; 12(9):e10621. PubMed ID: 33123434
[TBL] [Abstract][Full Text] [Related]
52. Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine.
Colman RJ; Dhaliwal J; Rosen MJ
Front Pediatr; 2021; 9():634739. PubMed ID: 33681110
[TBL] [Abstract][Full Text] [Related]
53. Ulcerative colitis.
Kobayashi T; Siegmund B; Le Berre C; Wei SC; Ferrante M; Shen B; Bernstein CN; Danese S; Peyrin-Biroulet L; Hibi T
Nat Rev Dis Primers; 2020 Sep; 6(1):74. PubMed ID: 32913180
[TBL] [Abstract][Full Text] [Related]
54. Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.
Czaja AJ
Dig Dis Sci; 2022 Nov; 67(11):4979-5005. PubMed ID: 35147819
[TBL] [Abstract][Full Text] [Related]
55. A Machine Learning Model Accurately Predicts Ulcerative Colitis Activity at One Year in Patients Treated with Anti-Tumour Necrosis Factor α Agents.
Popa IV; Burlacu A; Mihai C; Prelipcean CC
Medicina (Kaunas); 2020 Nov; 56(11):. PubMed ID: 33233514
[No Abstract] [Full Text] [Related]
56. In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis.
Zhou X; Yu M; Ma L; Fu J; Guo J; Lei J; Fu Z; Fu Y; Zhang Q; Zhang CY; Chen X
Nat Commun; 2022 Sep; 13(1):5700. PubMed ID: 36171212
[TBL] [Abstract][Full Text] [Related]
57. Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine.
Mukhtar MS; Mosli MH
Saudi J Gastroenterol; 2024 May; 30(3):126-137. PubMed ID: 38597333
[TBL] [Abstract][Full Text] [Related]
58. Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis.
Hindson J
Nat Rev Gastroenterol Hepatol; 2023 Sep; 20(9):559. PubMed ID: 37553497
[No Abstract] [Full Text] [Related]
59. Managing high-priced biologic agents: challenges and potential solutions.
Li M; Yeung K
J Manag Care Spec Pharm; 2021 Mar; 27(3):411-414. PubMed ID: 33645239
[No Abstract] [Full Text] [Related]
60. Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.
Hanzel J; Drobne D
Aliment Pharmacol Ther; 2023 Jun; 57(12):1469-1470. PubMed ID: 37243472
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
